Industries > Pharma > Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis

PUBLISHED: 22 March 2017
PAGES: 200
PRODUCT CODE: PHA0178
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0178 Categories: ,

The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 200-page report you will receive 89 tables and 50 figures – all unavailable elsewhere.

The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Report Scope
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027

• Submarket forecasts from 2017-2027:
 – Biologics
 – Aminosalicylates
 – Antibiotics
 – Corticosteroids
 – Immunomodulators

• Revenue forecast from 2017-2027 for 17 leading products:
 – Humira
 – Remicade
 – Lialda
 – Asacol
 – Pentasa
 – Xifaxan
 – Cimzia
 – Tysabri
 – Simponi
 – Canasa/Salofalk
 – Entyvio
 – Apriso
 – Medrol
 – Neoral
 – Entocort
 – Uceris
 – Azulfidine

Revenue forecasts from 2017-2027 for 11 countries:
 – US
 – Japan
 – Germany, France, UK, Spain and Italy (EU5)
 – Brazil, Russia, India and China (BRIC)

Discussions on research and development, including drug candidates in these classes:
 – Interleukin (IL) inhibitors
 – Cell-adhesion molecule (CAM) inhibitors
 – TNF-alpha inhibitors
 – Stem cell therapies
 – JAK inhibitors
 – Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Pharma Contract Manufacturing Market Report 2020-2030

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.

10 August 2020

READ

Visiongain Publishes Biologics Market Report 2020-2030

Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.

06 August 2020

READ

Visiongain Publishes Biochips Market Report 2020-2030

Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.

05 August 2020

READ

Visiongain Publishes Cell and Gene Supply Chain Services and Solutions Market Report 2020-2030

With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies.

03 August 2020

READ

Categories

Category